• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 502138 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414219554 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414219554 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Earnings Look Back: Seattle Genetics Is Up 3.6% Since Reporting Quarterly Results 1 Week Ago (SGEN)

Published on Sat, 05/18/2013 - 09:13
By Mallory Stone

A week ago on May 7th, 2013 Seattle Genetics (NASDAQ:SGEN) reported earnings and analysts, on average, expected a loss of $0.19 on sales of $53.6 million. Seattle Genetics actually reported a loss of $0.14 per share on sales of $57.3 million, beating EPS estimates by $0.05 and beating revenue estimates by $3.8 million. Shares of Seattle Genetics have climbed from $35.41 to $36.70, representing a gain of 3.6% since the company reported earnings 11 days ago.

In the past 52 weeks, shares of Seattle Genetics have traded between a low of $19.00 and a high of $39.00 and closed Thursday at $36.70, which is 93% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 1.0% while the 50-day MA has advanced 2.2%.

Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company's technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer.

Seattle Genetics (NASDAQ:SGEN) defies analysts with a current price ($36.70) 14.4% above its average consensus price target of $31.40. The stock should discover initial support at its 50-day moving average (MA) of $35.58 and subsequent support at its 200-day MA of $28.72.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Shares of Travelers Rise Above Previous ...

Shares of Travelers (NYSE:TRV) traded today at $97.70, breaking its 52-week high. Appr ...

Shares of Transglobe Energy Fall to a Ne...

Transglobe Energy (NASDAQ:TGA) traded today at a new 52-week low of $4.66. So far toda ...

Shares of Teleflex Have Risen Above Prev...

Shares of Teleflex (NYSE:TFX) traded today at $111.56, breaking its 52-week high. Appr ...

Southwest Gas: 52-Week High Recently Ecl...

Southwest Gas (NYSE:SWX) traded today at a new 52-week high of $56.15. So far today ap ...

Shares of Southwestern Energy Have Falle...

Shares of Southwestern Energy (NYSE:SWN) traded at a new 52-week low today of $31.28. ...

Shares of Sovran Self Storage Rise to a ...

Shares of Sovran Self Storage (NYSE:SSS) traded today at $82.98, breaking its 52-week h ...

Recent 52-Week High Exceeded in Shares o...

Sonic (NASDAQ:SONC) traded at a new 52-week high today of $24.92. So far today approxi ...

Super Micro Computer: The Winning Streak...

Super Micro Computer (NASDAQ:SMCI) traded today at a new 52-week high of $31.00. This ...